Can digestive enzymes help IBS and bloating?
Not as a general fix — there's no strong evidence that broad enzyme blends help IBS as a whole condition, though a few targeted enzymes show limited, promising results for specific triggers.
Quick answer
What the documentation supports
- Alpha-galactosidase for gas specifically from oligosaccharide-containing foods (mixed but real trial support).
- A small pilot trial of pancrelipase for cramping, bloating, abdominal pain and stool frequency in food-triggered IBS-diarrhea — promising, but limited by pilot-scale size.
- One controlled study of a soluble-fiber-plus-enzyme combination for bloating and abdominal pain — a combination product, so the effect can't be attributed to the enzymes alone.
- One 2026 real-world survey of a FODMAP-targeting enzyme blend reporting improvement in bloating and other symptoms — an uncontrolled pre-post cohort, not a randomized trial, so it cannot establish that the enzyme caused the improvement.
What it does not support
- Broad-spectrum enzyme blends as a fix for IBS as a whole condition — IBS has multiple underlying mechanisms (motility, visceral sensitivity, gut-brain signaling, microbiome) that a digestive enzyme doesn't address.
- A "best enzyme for IBS" ranking — the evidence doesn't support that level of specificity yet.
Is an over-the-counter product relevant here?
Alpha-galactosidase for specific oligosaccharide triggers, and some pilot-stage pancreatic enzyme or fiber-combination research — but no broad-spectrum blend is well-supported for IBS as a syndrome.
What research actually exists
There is no strong body of evidence that generic, broad-spectrum over-the-counter enzyme blends help IBS as a whole condition. IBS has multiple underlying mechanisms (motility, visceral sensitivity, gut-brain signaling, microbiome composition), and a digestive enzyme only addresses one narrow piece — breaking down specific food components — not the syndrome itself.
That said, a handful of smaller, more targeted studies point to real but limited effects: alpha-galactosidase shows mixed results specifically for gas from oligosaccharide-containing foods (more promising in people with a specific food trigger than as a general IBS treatment — see the alpha-galactosidase guide); pancrelipase (a pancreatic enzyme blend) improved cramping, bloating, abdominal pain and stool frequency in a small pilot trial of food-triggered IBS-diarrhea; a combination product (soluble fiber plus digestive enzymes) improved bloating and abdominal pain in one controlled study; and a 2026 real-world survey of people using a FODMAP-targeting enzyme blend reported improvement in bloating, gas and other symptoms — each promising, each limited by design.
Why each of these falls short of proving a general fix
The pancrelipase pilot was a small, randomized, double-blind, placebo-controlled crossover trial, but it was still a pilot — a limited number of participants, testing a specific enzyme blend in a specific subgroup (food-triggered IBS-diarrhea), not IBS broadly.
The soluble-fiber-plus-enzyme study tested a combination product, so the improvement in bloating and abdominal pain can't be attributed to the digestive enzymes alone — the fiber component may have driven some or all of the effect.
The 2026 study was an uncontrolled, open-label, pre-post cohort of people who had already purchased and chosen to use the product: there was no placebo group, no randomization, and no way to rule out expectation effects or the natural ebb and flow of IBS symptoms. It cannot establish that the enzyme blend caused the improvement.
- IBS itself should be diagnosed by a clinician — this page does not diagnose it.
- An enzyme supplement is a low-risk option to discuss with a clinician or dietitian, not a substitute for identifying your actual trigger foods or an underlying condition.
Sources: General evidence landscape drawn from published pilot and controlled studies on enzyme supplementation in IBS populations, referenced individually on the alpha-galactosidase page; Money et al., "Pilot study: a randomised, double blind, placebo controlled trial of pancrealipase for the treatment of postprandial irritable bowel syndrome-diarrhoea" — PMC3009417; "Effect of beta-glucan, inositol and digestive enzymes in GI symptoms of patients with IBS" — PubMed 21796867; Kaye et al., "FODMAP-Targeting Digestive Enzyme Blend for Management of Gastrointestinal Symptoms: A 'Real-World' Pre-Post Intervention Cohort Study", Gastro Hep Advances (2026) — PubMed 41908325. Last reviewed: July 29, 2026.